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Multiple myeloma (MM) is among the most frequent hematologic
malignancies. Despite recent treatment advances, MM remains an
incurable disease in the vast majority of cases. The course of the
disease is characterized by multiple relapses.
Pomalidomide is a third-generation, oral immunomodulatory
drug with activity in patients with relapsed and refractory MM. The
pivotal MM-003 trial (pomalidomide 4 mg per day d1− 21 q28 +
low dose dexamethasone (LoDEX) vs high dose dexamethasone)
showed improvement in median progression-free survival (PFS)
from 1.9 months with LoDEX to 4.0 months with pomalidomide/
LoDEX.1 A preplanned interim analysis of overall survival (OS)
showed superiority of pomalidomide. Toxicity of pomalidomide in
the MM-003 trial, however, was considerable, with 60% of patients
experiencing drug-related G3/4 toxicity. Neutropenia (48 vs 16%)
and pneumonia (13 vs 8%) were signiﬁcantly more common in the
pomalidomide arm. This resulted in frequent dose interruptions
(67%) and dose reductions (27%). This suggests that for the
majority of patients the 4 mg daily dosing schedule (4 mg daily on
21 of 28 days) is too toxic, and that strategies to deliver reduced
dosing of pomalidomide are of high practical relevance.
The drug costs of pomalidomide are high even for healthcare
systems in developed countries (Switzerland: 12.400 CHF per 4 week
cycle; US: US$ 13.700 per 4 week cycle). Interestingly, the
manufacturer chose a pricing model that is independent from the
capsule strength (costs for one capsule 1 mg=2 mg=3 mg=4 mg).
In patients requiring dose reductions due to hematologic toxicity,
daily dosing of reduced strength pomalidomide (for example, 2 mg
daily) is approved and suggested by the manufacturer. This delivers
50% less pomalidomide to the patient, albeit at 100% of the price of
full dosing. Given this discrepancy, one may think about alternative
strategies, such as delivering the 4 mg capsule strength on an
alternate day schedule, which would save 50% of the drug costs
compared to daily 2 mg. Obviously, this requires that pomalidomide
has adequate pharmacokinetic properties. The evidence supporting
the established vs alternative dosing schedules of pomalidomide is,
therefore, worth reconsidering.
ALTERNATIVE DOSING SCHEDULES
Due to its pharmacological characteristics, pomalidomide is well
suited for alternate day dosing; in contrast to other immunomo-
dulatory drugs (IMiDs), pomalidomide has the longest half-life (t½)
of all IMiDs with a mean of 7.5 h (t½ lenalidomide: 3 h) in patients
with MM.2
In a population pharmacokinetics analysis, Li et al.3 published a
model demonstrating a substantially deeper tissue/organ pene-
tration of pomalidomide in MM patients compared to healthy
subjects. The peripheral volume of distribution (V3/F) was
eightfold higher in patients with active MM (71.5 l) compared
with healthy participants (8.5 l). Correspondingly, the largest V3/F
was found in patients with stage III disease. As a result, the decline
of the plasma concentration at the terminal phase was slow
(Figure 1). These data make pomalidomide an ideal candidate for
alternate day dosing.
The early dose-ﬁnding studies with pomalidomide resulted in
conﬂicting data. Schey et al.4 examined the safety and tolerability
of pomalidomide in patients with relapsed refractory MM in the
ﬁrst-in-man phase I clinical trial in 2004. The main objective of the
study was to establish the maximum tolerated dose (MTD) of
pomalidomide. Seventeen percent (4/24) of the participants
developed deep vein thrombosis. The main hematologic dose-
limiting toxicity (DLT) was grade 4 neutropenia in patients taking
more than 2 mg per day (neutropenia ⩾ grade 3: 100%). MTD in
this patient population was therefore deﬁned as 2 mg daily Table 1.
Because of the toxicities observed, the same group undertook a
second dose-ﬁnding phase 1 study using alternate day adminis-
tration with the aim to potentially reduce toxicity while
maintaining efﬁcacy.5 Twenty patients with relapsed myeloma
were treated on alternate days. This schedule of pomalidomide
was associated with marked reduction of thrombotic episodes (no
events observed) and less severe myelosuppression (neutropenia
⩾ grad 3: 45%) while maintaining anti-myeloma activity (450%
partial response or better; 10% complete response). The median
OS and PFS were 33 and 10.5 months, respectively. MTD was
deﬁned as 5 mg on alternate days.
These trials laid the foundation for subsequent clinical develop-
ment. Lacy et al.6 conducted a phase II trial of pomalidomide in
combination with dexamethasone in 60 patients (40% with
lenalidomide-refractory disease) with less than three prior therapies.
Sixty patients received pomalidomide (2 mg daily) with dexametha-
sone 40 mg weekly. The overall response rate was 63% with 5% of
the patients achieving complete response. The most common
grade 3 or 4 toxicity was neutropenia in 31% of the patients.
Subsequently, Lacy et al.7 tested two different schedules in a
sequential non-randomized trial (4 mg for a 28/28-day cycle and 2mg
for a 28/28-day cycle) and showed that both dosing levels resulted in
similar activity in dual-refractory myeloma patients.7 These non-
randomized data conﬁrmed the remarkable activity of pomalidomide
but, at the same time, suggested that there may be no clinically
signiﬁcant advantage for 4 mg over the 2mg with daily dosing
schedules, while the 2mg dose appeared to be more tolerable.
Figure 1. Individual dose-normalized pomalidomide concentration
vs time proﬁles: healthy normal participants vs patients with MM3.
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The most recent phase 1 study was conducted by Richardson
et al.8 following a standard ‘3+3’ design to determine the MTD of
pomalidomide administered on days 1 to 21 daily, on a 28-day
cycle in patients with relapsed and refractory MM. No formal DLTs
were observed in the ﬁrst three patients enrolled at the 2 mg dose
level. However, one patient discontinued because of thrombocy-
topenia, and therefore, the investigators agreed to enroll three
additional patients in this cohort. Only one of the six patients
treated with 2 mg experienced a formal DLT (grade 3 fatigue). The
overall response rate seen in this small cohort of only six patients
was lower (⩾partial response: 1/6) than in the 4 mg cohort
(⩾ partial response: 4/14). Obviously, the study was not powered
for such a comparison, which is based on very small numbers. The
median PFS was 4.6 months for both doses, and the median OS
was 18.3 months in the intention to treat population. From these
data it was concluded to recommend a dose of 4 mg daily d1−21
q28 for the pivotal phase III trial (MM-003).
Very recently, Sehgal et al.9 revisited the pomalidomide dosing
question and evaluated the clinical and pharmacodynamic effects
of continuous (cohort 1: 2 mg for 28/28 cycle) or intermittent
dosing strategies (cohort 2: 4 mg for 21/28 cycle) of pomalido-
mide/dexamethasone in patients with lenalidomide-refractory
myeloma in a small randomized trial with 39 patients. The cohorts
were well balanced. In this study, comparable responses were
observed for both dosing schedules with signiﬁcantly more grade
3/4 side effects in the standard dose cohort (4 mg 21/28). Of note
and of critical importance for the treated patients, the event-free
survival was not different between both study arms (Figure 2).
Together, these results are consistent with the hypothesis that a
lower than the approved standard dosage of pomalidomide (4 mg
on 21/28 days) may be sufﬁcient to exploit the anti-myeloma
activity of pomalidomide in the clinical setting, while reducing the
incidence and severity of side effects.
Looking ahead, the use of pomalidomide for MM, treatment
duration and hence pomalidomide-related treatment costs are
likely to signiﬁcantly rise over the next years. The standard
pomalidomide schedule currently serves as a backbone in phase III
trials for patients with double refractory MM to which novel
classes of agents such as monoclonal antibodies are being added
in the experimental arm. In particular, the addition of daratumu-
mab might lead to signiﬁcantly increased treatment durations
according to the respective data presented at ASH 2016. Perhaps
not surprisingly, this combination with standard dose 4 mg daily
pomalidomide caused signiﬁcant hematological toxicity, with 46%
of patients requiring pomalidomide dose reductions.10 From this
perspective too it appears essential for patients and the healthcare
system alike that the pomalidomide backbone therapy is
performed with the lowest possible clinical and ﬁnancial toxicity,
while maintaining its clinical efﬁcacy.
Very few trials, sadly, are asking major strategic questions
beyond drug approval. One of the big issues today is that the cost
of cancer care has increased dramatically, and still few trials are
addressing cost effectiveness issues. More bluntly, given that the
number of cancer (and myeloma!) patients is predicted to double
between 2015 and 2030, and in the light of such signiﬁcant drug
costs, public and academic research likewise must ask whether we
Table 1. Summary of available clinical efﬁcacy data of pomalidomide in multiple myeloma trials
Trial Ph N Regimen Dose schedule/MTD ORR % DCR %
(⩽ SD)
Neutropenia⩾ grade 3 PFS; OS (months)
Schey et al.4 I 24 Pom MTD= 2 mg per day 54 490 58% (patients taking
4 2mg 100%)
9.7; 22.5
Streetly et al.5 I 20 Pom ± Dex MTD= 5 mg on
alternate days
50 90 45% 10.5; 33
Richardson et al.8 I 38 Pom ± Dex MTD= 4 mg 21 NA 53% (patients taking
4 2mg 60%)
4.6; 18.3
Lacy et al.6 II 60 Pom/Dex 2 mg (28/28)+DXM 63 88 31% 11.6; 76% at 2 years
Leleu et al.13 II
Arm A 43 Pom/Dex 4 mg (21/28)+DXM 30 79 65% NA
Arm B 40 Pom/Dex 4 mg (28/28)+DXM 47 85 58% NA
Lacy et al.7 II
Cohort A 35 Pom/Dex 2 mg (28/28)+DXM 49 82 51% 6.5; 78% at 6 months
Cohort B 35 Pom/Dex 4 mg (28/28)+DXM 43 74 66% 3.2; 67% at 6 months
San Miguel MM-0031 III
Cohort A 302 Pom/Dex 4 mg (21/28)+DXM 21 82 48% 4.0; 12.7
Cohort B 153 Dex DXM 3 62 16% 1.9; 8.1
Sehgal et al.9 II
Cohort 1 19 Pom/Dex 2mg (28/28) 21 NA 42% 4.3; 21.7
Cohort 2 20 Pom/Dex 4mg (21/28) 45 NA 45% 5.1; 17.7
Abbreviations: DCR, disease control rate; DXM, dexamethasone; MTD, maximum tolerated dose; ORR, overall response rate; OS, overall survival; PFS, progression-free
survival; SD, stable disease.
Figure 2. Kaplan−Meier plot comparing event-free survival in the
cohort 1 (2 mg 28/28) and 2 (4 mg 21/28).9
Letters to the Editor
1988
Leukemia (2017) 1987 – 2008
can deliver equivalent quality of care and therapeutic efﬁcacy to
more patients without a signiﬁcant increase in ﬁnancial resources.
The best possible use of highly active, but very expensive drugs
will be a cornerstone in such a strategy. Pomalidomide might be
one good example of how substantial amounts of money may be
saved, probably without affecting patient outcome by using a
different dose or schedule than in the registration trial. Obviously,
the conduct of such dose reduction trials that address the clinical
efﬁcacy of more cost-effective treatment schedules are not in the
short-term interest of pharmaceutical companies. Such trials are,
therefore, only feasible with ﬁnancial support from academic and
public agencies or non-commercial foundations. Indeed, the
myeloma research community has a track record in trials that
optimized the use of an established drug. For instance,
bortezomib is now given subcutaneously11 and for elderly
patients on a weekly dosing schedule.12
We conclude that the optimal dosing regimen of pomalidomide
is unclear. The current daily 4 mg treatment standard is based on
very little comparative data and raises questions from a toxicity
and cost effectiveness perspective, which are highly relevant for
our patients and the health care systems worldwide. In our
opinion there is a scientiﬁc rationale to use pomalidomide on
alternate days, especially in patients who need dose reductions or
are considered not to tolerate the full registered pomalidomide
dose.
In case the data discussed here already prompted clinicians to
use an alternate pomalidomide dosing schedule and in the
absence of a prospective clinical trial, we propose to collect clinical
data and outcome variables of such patients. In addition, the
authors would be happy to coordinate such an effort in a
framework of an international, prospective cohort study.
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Acute lymphoblastic leukemia (ALL) is among the most curable
childhood cancers with a 90% overall survival in the good-risk
category.1 Though the remission and cure rates among newly
diagnosed patients have improved, the prognosis for those with
relapsed disease remains poor. Better risk stratiﬁcation integrating
cytogenetics and genomics has enabled improvements in therapy
and prediction of relapse. Recently the clinical utility of
comprehensive genomic proﬁling (CGP) has been recognized, in
particular, for risk stratiﬁcation of about 25–30% of childhood ALL
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